EXELIXIS, INC. (EXEL) stock intrinsic value fair value estimate & owner earnings analysis

Exelixis is an oncology biotechnology company built almost entirely around one drug: cabozantinib, sold as Cabometyx (advanced kidney cancer, liver cancer, and other tumor types) and Cometriq (medullary thyroid cancer). Cabozantinib drives essentially all of the company's roughly $2.3 billion in annual revenue today. The central fact shaping this valuation is patent timing. Cabozantinib's original composition-of-matter patent, which has provided the broadest protection since the drug launched, expired in August 2026. What stands between Cabometyx and generic competition now is a set of later, narrower patents covering specific salt forms, formulations, and methods of treatment, which run out in stages between 2030 and 2033. Several generic manufacturers (MSN, Azurity, and others) have already filed applications challenging these patents, and a consolidated patent trial is scheduled for November 2026. One challenger, Sun, settled with Exelixis in December 2025 on undisclosed terms rather than litigate to a verdict, which is the kind of negotiated outcome that often delays, rather than eliminates, generic entry. The outcome of the November 2026 trial will materially clarify how much runway cabozantinib has left, and we treat that as a real, near-term swing factor rather than something to be waved away with an optimistic assumption that today's growth simply continues. Exelixis' most important answer to this patent cliff is zanzalintinib, its next-generation oral cancer drug. It has an FDA decision due December 3, 2026 for colorectal cancer, with additional pivotal trials underway in other tumor types. We treat zanzalintinib as a credible, filing-supported replacement candidate, but not a guaranteed one: colorectal cancer is a crowded market, and how well zanzalintinib performs commercially, and how many additional indications it eventually wins, is genuinely uncertain today. We build our estimate of the company's normal earning power from cash actually generated by the business, after removing stock-based compensation (a real cost to shareholders, since it dilutes them, even though it doesn't use cash) and the portion of capital spending that goes toward growing the business rather than maintaining it. Because both cash flow and net income for Exelixis swing significantly from one year to the next, driven mostly by collaboration and milestone payment timing and by a multi-year tax accounting effect tied to a 2022 change in how research spending is treated for tax purposes, we anchor our estimate on the middle year of the last five years of results rather than the most recent (and unusually strong) year alone. Note that 2025's results, while real cash generation, benefited from a favorable swing in this tax-timing item that we do not expect to persist at the same magnitude, so we did not use it as the base level from which we project forward. Our bear case assumes Exelixis loses the November 2026 trial, generic cabozantinib enters as early as 2027-2028, and pricing erodes quickly the way it typically does for oral cancer drugs once true generic competition arrives. In this case, zanzalintinib underperforms in a competitive colorectal cancer market and its other trials disappoint, leaving only a much smaller, low-growth royalty-like business. This produces a value near $5 per share. Our base case assumes Exelixis prevails or reaches further negotiated settlements similar to the Sun agreement, pushing meaningful generic competition out toward 2030-2032 in line with the later patents' actual expiration dates. Zanzalintinib is approved in colorectal cancer in December 2026 and expands into additional indications over the following several years, partially offsetting cabozantinib's eventual decline. Under this path, earnings grow moderately through about 2030, step down as the remaining patents lapse and generics arrive in the early 2030s, and then stabilize at a lower, sustainable level built primarily around zanzalintinib. This produces a value near $17 per share. Our bull case assumes Exelixis wins the litigation outright, holds its remaining patents to their full stated terms, and zanzalintinib succeeds broadly across multiple cancer types, becoming a genuine second pillar alongside cabozantinib rather than just a replacement for it. This produces a value near $50 per share, though a large share of that figure (roughly two-thirds) rests on the value of earnings well beyond the next ten years, which we flag because it means the bull case leans heavily on Exelixis successfully repeating its cabozantinib success with zanzalintinib and beyond. We explicitly did not assume cabozantinib's sales simply continue growing forever, or even hold flat indefinitely, past its disclosed patent expiration dates; nor did we assume they collapse to zero. Instead we built a case-by-case path that reflects the actual, disclosed legal and regulatory calendar, weighted by how much we think Exelixis' pipeline can realistically replace what is lost. Exelixis carries a large net cash position and minimal debt, giving it real flexibility to invest in its pipeline or return capital to shareholders (it has an active share buyback program) regardless of which scenario unfolds; we treat this as a supportive, but not scenario-changing, factor. Given the wide range between our downside and base-case outcomes here, which reflects a business whose fate depends heavily on two dated, resolvable events, the margin-of-safety price sits at a meaningful discount to our base-case estimate, around $8-9 per share. We would also weight our view more heavily toward the upside case once the November 2026 patent trial and the December 2026 zanzalintinib approval decision are actually known, since either outcome will substantially clarify which of these scenarios is closer to reality.